The FDA granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas/Seattle Genetics) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/-L1 (programmed death-1 and its ligand) inhibitor and platinum-containing chemotherapy before or after surgery.
Enfortumab vedotin-ejfv is a first-in-class antibody–drug conjugate directed against nectin-4, a protein located on the surface of cells and highly